Claims
- 1. A method for treating dementia or a memory disorder in a subject in need thereof comprising co-therapy with a therapeutically effective amount of an acetylcholinesterase inhibitor and a compound of the formula I:
- 2. The method of claim 1 wherein the compound of formula I is topiramate.
- 3. The method of claim 2, wherein the amount of topiramate is from about 10 to about 650 mg daily.
- 4. The method of claim 3, wherein the amount of topiramate is from about 25 to about 325 mg once or twice daily.
- 5. The method of claim 1, wherein the acetylcholinesterase inhibitor is selected from the group consisting of galantamine, rivastigmine, donepezil, tacrine and metrifonate.
- 6. The method of claim 5, wherein the acetylcholinesterase inhibitor is galantamine.
- 7. The method of claim 6, wherein the amount of galantamine is from about 2 to about 32 mg daily.
- 8. The method of claim 7, wherein the amount of galantamine is from about 4 to about 24 mg daily.
- 9. The method of claim 1, wherein the acetylcholinesterase inhibitor is galantamine and the compound of formula I is topiramate.
- 10. The method of claim 1, wherein the dementia is selected from the group consisting of dementia as a result of Alzheimer's disease, vascular related dementia, multi-infarct related dementia, dementia as a result of head trauma, dementia as a result of diffuse brain damage, dementia pugilistica, dementia as a result of Huntington's disease, dementia as a result of alcoholism, dementia as a result of diffuse white matter disease, dementia associated with Parkinson's disease, dementia as a result of Lewy body disease, dementia as a result of Pick's disease, dementia as a result of multisystem degeneration, dementia as a result of progressive supranuclear palsy, dementia associated with the ALS-Parkinson's-Dementia complex of Guam, frontal lobe dementia, and dementia as a result of cortical basal degeneration.
- 11. The method of claim 10, wherein the dementia is dementia as a result of Alzheimer's disease.
- 12. The method of claim 1, wherein the memory disorder is selected from the group consisting of memory loss, diminished mental capacity, mental deterioration and loss of cognition.
- 13. A method for treating behavioral, psychiatric or psychological manifestations or symptoms of dementia or a memory disorder in a subject in need thereof comprising co-therapy with a therapeutically effective amount of an acetylcholinesterase inhibitor and a compound of the formula I:
- 14. The method of claim 13 wherein the compound of formula I is topiramate.
- 15. The method of claim 14, wherein the amount of topiramate is from about 10 to about 650 mg daily.
- 16. The method of claim 15, wherein the amount of topiramate is of from about 25 to about 325 mg once or twice daily.
- 17. The method of claim 13, wherein the acetylcholinesterase inhibitor is selected from the group consisting of galantamine, rivastigmine, donepezil, tacrine and metrifonate.
- 18. The method of claim 17, wherein the acetylcholinesterase inhibitor is galantamine.
- 19. The method of claim 18, wherein the amount of galantamine is from about 2 to about 32 mg daily.
- 20. The method of claim 19, wherein the amount of galantamine is from about 4 to about 32 mg daily.
- 21. The method of claim 13, wherein the acetylcholinesterase inhibitor is galantamine and the compound of formula I is topiramate.
- 22. A pharmaceutical composition comprising galantamine, topiramate and a pharmaceutically acceptable carrier.
- 23. A pharmaceutical composition made by mixing galantamine, topiramate and a pharmaceutically acceptable carrier.
- 24. A process for making a pharmaceutical composition comprising mixing galantamine, topiramate and a pharmaceutically acceptable carrier.
- 26. The use of a therapeutically effective amount of topiramate and galantamine in the preparation of a medicament for treating (a) dementia, (b) memory loss, (c) mental deterioration, (d) diminished mental capacity, (e) loss of cognition or (f) behavioral, psychiatric and/or psychological manifestations or symptoms of dementia or a memory disorder in a subject in need thereof.
CROSS REFERENCE TO RELATED APPLICATION
[0001] This application claims priority from U.S. provisional application Serial No. 60/315,978, filed Aug. 30, 2001, the contents of which are hereby incorporated by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60315978 |
Aug 2001 |
US |